ADMA Biologics Inc (ADMA)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 219,553 | 88,942 | 35,265 | 1,173 | -19,072 |
| Revenue | US$ in thousands | 426,454 | 258,215 | 154,080 | 80,943 | 42,220 |
| Gross profit margin | 51.48% | 34.44% | 22.89% | 1.45% | -45.17% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $219,553K ÷ $426,454K
= 51.48%
The gross profit margin of ADMA Biologics Inc has shown significant improvement over the past few years.
As of December 31, 2020, the company had a negative gross profit margin of -45.17%, indicating that the cost of goods sold exceeded the revenue generated from sales. This could suggest inefficiencies in production or pricing strategies.
However, by December 31, 2021, the gross profit margin had improved to 1.45%, although it was still low, indicating that the company was able to better manage its costs and improve its pricing strategy.
Subsequent years showed even more substantial improvements, with the gross profit margin reaching 22.89% by December 31, 2022, 34.44% by December 31, 2023, and a significant increase to 51.48% by December 31, 2024. These improvements suggest that ADMA Biologics Inc was able to increase its revenue relative to its cost of goods sold, indicating a more efficient operation and potentially better pricing power in the market.
Overall, the trend in the gross profit margin indicates that ADMA Biologics Inc has made significant strides in improving its profitability and operational efficiency over the years covered in the data provided.
Peer comparison
Dec 31, 2024